Skip to main content
. 2023 Feb 12;23:63. doi: 10.1186/s12905-022-02140-y

Table 1.

General characteristics of population based on case and control groups

Control (n = 105) Case (n = 105) P value
Demographic characteristic
Age (y) 55.41 ± 7.14 55.33 ± 7.04 0.94
Albumin (g/dl) 8.37 ± 6.76 14.40 ± 11.94  < 0.001
ACR 18.66 ± 5.92 232.18 ± 114.07  < 0.001
Diabetes duration (y) 7.56 ± 2.17 7.60 ± 2.21 0.88
Blood pressure
SBP (mmHg) 129.04 ± 98.88 126.59 ± 17.27 0.80
DBP (mmHg) 80.10 ± 11.76 82.80 ± 13.09 0.12
Anthropometry characteristic
Body weight (kg) 71.589 ± 11.50 73.400 ± 13.83 0.30
Height (cm) 161.17 ± 5.91 160.68 ± 6.29 0.56
BMI (kg/m2) 27.510 ± 4.39 28.686 ± 4.74 0.06
Blood parameters
Hb (mg/dl) 12.630 ± 1.22 12.610 ± 1.37 0.91
FBS (mg/dl) 154.19 ± 45.03 167.10 ± 50.62 0.05
BS (mg/dl) 207.10 ± 54.35 217.75 ± 53.23 0.15
HbA1c (%) 8.031 ± 1.29 8.660 ± 1.41  < 0.001
Cholesterol (mg/dl) 175.38 ± 32.42 185.15 ± 38.12 0.05
TG (mg/dl) 162.25 ± 57.91 167.26 ± 65.68 0.56
LDL (mg/dl) 94.60 ± 29.47 106.86 ± 31.77  < 0.001
HDL (mg/dl) 46.37 ± 9.25 45.05 ± 9.26 0.30
Cr (mg/dl) 0.87 ± 0.17 0.92 ± 0.16 0.03
BUN (mg/dl) 15.17 ± 3.86 15.79 ± 4.55 0.29
Qualitative variables
PA (met-h/w)
 Low (> 600) 37 (17.6) 31 (14.8) 0.12
 Moderate (600–3000) 28 (13.4) 42 (20)
 High (< 3000) 40 (19) 32 (15.2)
Medical history
Positive CVD history 23 (11) 24 (11.4) 0.86
Medication usage
ARBs 45 (21.4) 60 (28.6) 0.03
ACEIs 21 (10) 44 (21) 0.001
Beta blockers 18 (8.6) 20 (9.5) 0.56
Metformin 104 (49.5) 104 (49.5) 0.75
sulfonylurea 62 (29.5) 71 (33.8) 0.19
Insulin 35 (16.7) 26 (12.4) 0.17

Data are presented as mean ± SD or number (percent)

Independent sample T test and chi square were used

Significant items with a P value ≤ 0.05 are bolded

ACR Albumin creatinine ratio, SBP Systolic blood pressure, DBP Diastolic blood pressure, BMI Body mass index, Hb Hemoglobin, FBS Fasting blood sugar, BS Blood sugar, TG Triglycerides, HDL High density lipoprotein, LDL Low density lipoprotein, CR Creatinine, BUN Blood urea nitrogen, DASH Dietary approach to stop hypertension, PA Physical activity, met Metabolic equivalent, CVD Cardiovascular disease, ARBs Angiotensin receptor blockers, ACEIs Angiotensin converting enzyme inhibitors